Molecular Origins of Cancer: Molecular Basis of Colorectal Cancer

Por Markowitz, Sanford D., Bertagnolli, Monica M.
Publicado em 2009

Expanding Public-Private Collaborations to Enhance Cancer Drug Development: A Report of the Institute of Medicine’s Workshop Series, “Implementing a National Cancer Clinical Trials...

Por Bertagnolli, Monica M., Canetta, Renzo, Nass, Sharyl J.
Publicado no Oncologist (2014)

Chronic cyclooxygenase-2 inhibition promotes myofibroblast-associated intestinal fibrosis

Por Davids, Jennifer S., Carothers, Adelaide M., Damas, Beatrice C., Bertagnolli, Monica M.
Publicado em 2010

Persistent Cox-2 inhibition downregulates NF-κB resulting in chronic intestinal inflammation in the Min/+ mouse model of colon tumorigenesis

Por Carothers, Adelaide M., Davids, Jennifer S., Damas, Beatrice C., Bertagnolli, Monica M.
Publicado em 2010

The Influence of UGT 1A6 Variants and Aspirin Use in a Randomized Trial of Celecoxib for Prevention of Colorectal Adenoma

Por Chan, Andrew T., Hsu, Meier, Zauber, Ann G., Hawk, Ernest T., Bertagnolli, Monica M.
Publicado em 2011

Statin Use and Colorectal Adenoma Risk: Results from the Adenoma Prevention with Celecoxib (APC) Trial

Por Bertagnolli, Monica M., Hsu, Meier, Hawk, Ernest T., Eagle, Craig J., Zauber, Ann G.
Publicado em 2010

C-reactive Protein and Risk of Colorectal Adenoma According to Celecoxib Treatment

Por Chan, Andrew T., Sima, Camelia S., Zauber, Ann G., Ridker, Paul M, Hawk, Ernest T., Bertagnolli, Monica M.
Publicado em 2011

Celecoxib pathways: pharmacokinetics and pharmacodynamics

Por Gong, Li, Thorn, Caroline F., Bertagnolli, Monica M., Grosser, Tilo, Altman, Russ B., Klein, Teri E.
Publicado em 2012

Mesenchymal stromal cell mutations and wound healing contribute to the etiology of desmoid tumors

Por Carothers, Adelaide M., Rizvi, Hira, Hasson, Rian M., Heit, Yvonne I., Davids, Jennifer S., Bertagnolli, Monica M., Cho, Nancy L.
Publicado em 2011

Estrogen receptor α or β loss in the colon of Min/+ mice promotes crypt expansion and impairs TGFβ and HNF3β signaling

Por Hasson, Rian M., Briggs, Alexandra, Carothers, Adelaide M., Davids, Jennifer S., Wang, Jiping, Javid, Sara H., Cho, Nancy L., Bertagnolli, Monica M.
Publicado em 2014

Cytochrome P450 2C9 Variants Influence Response to Celecoxib for Prevention of Colorectal Adenoma

Por Chan, Andrew T., Zauber, Ann G., Hsu, Meier, Breazna, Aurora, Hunter, David J., Rosenstein, Rebecca B., Eagle, Craig J., Hawk, Ernest T., Bertagnolli, Monica M.
Publicado em 2009

Microsatellite Instability and Loss of Heterozygosity at Chromosomal Location 18q: Prospective Evaluation of Biomarkers for Stages II and III Colon Cancer—A Study of CALGB 9581 and...

Por Bertagnolli, Monica M., Redston, Mark, Compton, Carolyn C., Niedzwiecki, Donna, Mayer, Robert J., Goldberg, Richard M., Colacchio, Thomas A., Saltz, Leonard B., Warren, Robert S.
Publicado em 2011

Prognostic and Predictive Blood-Based Biomarkers in Patients with Advanced Pancreatic Cancer: Results from CALGB80303 (Alliance)

Por Nixon, Andrew B., Pang, Herbert, Starr, Mark D., Friedman, Paula N., Bertagnolli, Monica M., Kindler, Hedy L., Goldberg, Richard M., Venook, Alan P., Hurwitz, Herbert I.
Publicado no Clin Cancer Res (2013)

MUCH OF THE POPULATION GENETIC RISK OF COLORECTAL CANCER IS LIKELY TO BE MEDIATED THROUGH SUSCEPTIBILITY TO ADENOMAS

Por Carvajal-Carmona, Luis G., Zauber, Ann G., Jones, Angela M., Howarth, Kimberley, Wang, Jiping, Cheng, Timothy, Riddell, Robert, Lanas, Angel, Morton, Dion, Bertagnolli, Monica M., Tomlinson, Ian
Publicado em 2012

Prognostic Impact of Deficient DNA Mismatch Repair in Patients With Stage III Colon Cancer From a Randomized Trial of FOLFOX-Based Adjuvant Chemotherapy

Por Sinicrope, Frank A., Mahoney, Michelle R., Smyrk, Thomas C., Thibodeau, Stephen N., Warren, Robert S., Bertagnolli, Monica M., Nelson, Garth D., Goldberg, Richard M., Sargent, Daniel J., Alberts, Steven R.
Publicado em 2013

Microsatellite Instability Predicts Improved Response to Adjuvant Therapy With Irinotecan, Fluorouracil, and Leucovorin in Stage III Colon Cancer: Cancer and Leukemia Group B Proto...

Por Bertagnolli, Monica M., Niedzwiecki, Donna, Compton, Carolyn C., Hahn, Hejin P., Hall, Margaret, Damas, Beatrice, Jewell, Scott D., Mayer, Robert J., Goldberg, Richard M., Saltz, Leonard B., Warren, Robert S., Redston, Mark
Publicado em 2009

KRAS and KIT Gatekeeper Mutations Confer Polyclonal Primary Imatinib Resistance in GI Stromal Tumors: Relevance of Concomitant Phosphatidylinositol 3-Kinase/AKT Dysregulation

Por Serrano, César, Wang, Yuexiang, Mariño-Enríquez, Adrián, Lee, Jen-Chieh, Ravegnini, Gloria, Morgan, Jeffrey A., Bertagnolli, Monica M., Beadling, Carol, Demetri, George D., Corless, Christopher L., Heinrich, Michael C., Fletcher, Jonathan A.
Publicado no J Clin Oncol (2015)

p27(Kip1) in Stage III Colon Cancer: Implications for Outcome Following Adjuvant Chemotherapy in CALGB 89803

Por Bertagnolli, Monica M., Warren, Robert S., Niedzwiecki, Donna, Mueller, Elke, Compton, Carolyn C., Redston, Mark, Hall, Margaret, Hahn, Hejin P., Jewell, Scott D., Mayer, Robert J., Goldberg, Richard M., Saltz, Leonard B., Loda, Massimo
Publicado em 2009

Association of TP53 Mutational Status and Gender with Survival After Adjuvant Treatment for Stage III Colon Cancer: Results of CALGB 89803

Por Warren, Robert S., Atreya, Chloe E., Niedzwiecki, Donna, Weinberg, Vivian K., Donner, David B., Mayer, Robert J., Goldberg, Richard M., Compton, Carolyn C., Zuraek, Marlene B., Ye, Cynthia, Saltz, Leonard B., Bertagnolli, Monica M.
Publicado em 2013

KRAS Mutation in Stage III Colon Cancer and Clinical Outcome Following Intergroup Trial CALGB 89803

Por Ogino, Shuji, Meyerhardt, Jeffrey A., Irahara, Natsumi, Niedzwiecki, Donna, Hollis, Donna, Saltz, Leonard B., Mayer, Robert J., Schaefer, Paul, Whittom, Renaud, Hantel, Alexander, Benson, Al B., Goldberg, Richard M., Bertagnolli, Monica M., Fuchs, Charles S.
Publicado em 2009